Apr 20, 2022 / 07:30PM GMT
Gerri Henwood - Baudax Bio, Inc. - President and CEO
Good afternoon. Thanks very much for your time and attention. Still being awake after lunch at all. I appreciate the chance to tell you about my favorite topic, Baudax Bio. The lawyers of course have threatened me within an inch if I don't tell you to look at all of our filings before you make any investment decisions.
So Baudax Bio is a company that has a commercial product and just so approved in February of 2020, just in time for the pandemic. It's a product that is a once a day, 24 hours less thing, not opioid, analgesic for pain such as after surgery. And it's used in hospitals and an ambulatory care setting. We also have a pipeline of acute care products directed primarily at anesthesia; offering, we think, some important advances over the good products that are currently available, but that would allow for more cost effective and timely treatment.
Financial position of the company is not excessively capitalized, as you will note with $16 million on the balance sheet as of the filing of the K, and that was as of 12/31 with the
Baudax Bio Inc at Noble Capital Markets Investor Conference (Virtual) Transcript
Feb 13, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers